/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present

10x Genomics (NASDAQ: TXG - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Profitability This table compares 10x Genomics and

Aaron Wealth Advisors LLC purchased a new position in shares of 10x Genomics (NASDAQ: TXG) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 39,530 shares of the company's stock, valued at approximately $462,000. Other large investors also recently bought and sold

Torex Gold Resources Inc. (TSE: TXG - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of C$52.17 and traded as high as C$65.02. Torex Gold Resources shares last traded at C$64.75, with a volume of 502,160 shares. Analyst Upgrades and Downgrades A number

Federated Hermes Inc. raised its holdings in shares of 10x Genomics (NASDAQ: TXG) by 665.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 787,522 shares of the company's stock after acquiring an additional 684,659 shares during

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region PLEASANTON, Calif. and SYDNEY , Nov. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc.

PLEASANTON, Calif. , Nov. 11, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research Healthcare Conference 2025 on Tuesday, November 18, at 11:20 a.m.

10x Genomics, Inc. ( TXG ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Adam Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Madeline Mollman Puneet Souda - Leerink Partners LLC, Research Division Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lu Li - UBS Investment Bank, Research Division Michael Ryskin - BofA Securities, Research Division Justin Bowers - Deutsche Bank AG, Research Division Jaden Rismay - JPMorgan Chase & Co, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Presentation Operator Thank you for standing by. Welcome to the 10X Genomics' Third Quarter 2025 Earnings Conference Call.

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

10x Genomics (TXG) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.